Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy

BJU International

Volumn 108, Issue 7, 2011, Pages 1086-1091

  Misra, Dipika ^a   Xie, Wanling ^b   Regan, Meredith M ^b   Ross, Robert W ^c   Lee, Gwo Shu ^c   Germain, Doris ^a   Kantoff, Philip W ^c   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

androgen deprivation therapy; androgen receptor; polymorphisms; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CAG REPEAT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; SURVIVAL TIME;

AGED; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; GERM CELLS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 80052812510     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10037.x     Document Type: Article

References (17)

1. Ross RW, Xie W, Regan MM, et al,. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112: 1247-53 (Pubitemid 351429739)
2. Hirawat S, Budman DR, Kreis W,. The androgen receptor: structure, mutations, and antiandrogens. Cancer Invest 2003; 21: 400-17 (Pubitemid 37055673)
3. Giovannucci E, Stampfer MJ, Krithivas K, et al,. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997; 94: 3320-3 (Pubitemid 27157309)
4. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H,. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672-6 (Pubitemid 29458864)
5. Ingles SA, Ross RK, Yu MC, et al,. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166-70 (Pubitemid 27034793)
6. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER,. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599-608 (Pubitemid 27431569)
7. Ding D, Xu L, Menon M, Reddy GP, Barrack ER,. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 2004; 58: 23-32 (Pubitemid 38057985)
8. Hardy DO, Scher HI, Bogenreider T, et al,. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996; 81: 4400-5 (Pubitemid 26412051)
9. Edwards SM, Badzioch MD, Minter R, et al,. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 1999; 84: 458-65
10. Suzuki H, Akakura K, Komiya A, et al,. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 2002; 51: 219-24 (Pubitemid 34492643)
11. Shimbo M, Suzuki H, Kamiya N, et al,. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur Urol 2005; 47: 557-63 (Pubitemid 40357910)
12. Klotz L, Correia A, Zhang W,. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 179-83 (Pubitemid 43118083)
13. Ross RW, Oh WK, Xie W, et al,. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008; 26: 842-7 (Pubitemid 351398074)
14. Oh WK, Hayes J, Evan C, et al,. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006; 5: 61-6
15. Powell IJ, Land SJ, Dey J, et al,. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 2005; 103: 528-37
16. Nam RK, Elhaji Y, Krahn MD, et al,. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000; 164: 567-72 (Pubitemid 30481985)
17. Sircar K, Gottlieb B, Alvarado C, et al,. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer Prostatic Dis 2007; 10: 360-8 (Pubitemid 350238085)